Business Context and Reporting Period
Company: A.P. Pharma, Inc. (Note: Metadata referenced "Heron Therapeutics," but the filing text identifies the registrant as A.P. Pharma, Inc.)
Reporting Period: Quarterly period ended September 30, 2010 (Form 10-Q).
Business Overview: A specialty pharmaceutical company developing products using proprietary Biochronomer polymer-based drug delivery technology. The primary focus is the lead product candidate APF530, designed for the prevention of chemotherapy-induced nausea and vomiting (CINV). Other pipeline products have been temporarily deferred to focus resources on APF530.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Balance Sheet (Sep 30, 2010) |
|---|---|---|---|
| Contract Revenue | $351 | $1,122 | - |
| Operating Expenses | $1,986 | $9,323 | - |
| Operating Loss | $(1,635) | $(8,201) | - |
| Net Loss | $(1,672) | $(5,750) | - |
| Cash and Cash Equivalents | - | - | $3,015 |
| Working Capital | - | - | $2,260 |
| Accumulated Deficit | - | - | $(146,829) |
| Net Cash Used in Operating Activities | - | $(4,563) | - |
Note: The filing does not provide explicit margin percentages due to the lack of profitability. Revenue is derived primarily from collaborative research and development agreements.
Material Changes vs. Prior Period
- Revenue: Contract revenue for the three months ended September 30, 2010, decreased significantly to $351,000 from $1.1 million in the same period in 2009. The 2009 period included $1.0 million recognized upon the termination of an agreement with RHEI Pharmaceuticals. For the nine months, revenue remained relatively flat at $1.1 million compared to $1.1 million in 2009.
- Operating Expenses: Total operating expenses for the three months decreased to $1.986 million from $2.33 million in 2009, driven by a reduction in General and Administrative (G&A) expenses. However, for the nine months, total operating expenses increased slightly to $9.323 million from $9.281 million in 2009, primarily due to G&A costs related to the resignation of the former CEO.
- Liquidity: Cash and cash equivalents decreased by approximately $4.6 million from December 31, 2009 ($7.593 million) to September 30, 2010 ($3.015 million), primarily due to operating losses, partially offset by a $2.5 million milestone payment received in January 2010 from the Paul Royalty Fund.
- Discontinued Operations: The company recorded a loss from discontinued operations of $36,000 for the three months and $47,000 for the nine months ended September 30, 2010, related to changes in estimates for gross profit guarantees on a previously sold cosmeceutical business. There was no such loss in the comparable 2009 periods.
Guidance, Outlook, Risks, and Unusual Items
Regulatory Status and Outlook
In March 2010, the company received a Complete Response Letter (CRL) from the FDA regarding the New Drug Application (NDA) for APF530. The FDA cited concerns regarding the dosing system, chemistry/manufacturing/controls (including facility inspection deficiencies and a requirement for terminal sterilization), and clinical data (requiring re-analysis and additional bioavailability/QT studies). The company intends to hold an End of Review meeting with the FDA to clarify actions required for resubmission, but no date has been set.
Liquidity and Going Concern
The company has an accumulated deficit of $146.8 million and incurred significant operating losses. Management believes current cash resources ($3.0 million) are sufficient to fund operations into the first quarter of 2011, assuming continued deferral of discretionary activities. The company is actively seeking additional financing through collaborative arrangements, equity offerings, or debt financing. Failure to secure funding may require further reduction of activities or discontinuation of operations.
Unusual Items
- Stock-Based Compensation: Significant stock-based compensation expense of $1.386 million was recorded for the nine months ended September 30, 2010, including accelerated vesting related to the resignation of the former CEO.
- Milestone Payment: A $2.5 million milestone payment was received in January 2010 from the Paul Royalty Fund, which was recognized as a gain on the sale of royalty interest in the nine-month period.
Risk Factors
- Delisting Risk: The company received notice from Nasdaq that its stock price had fallen below the $1.00 minimum bid price requirement. It has until November 15, 2010, to regain compliance. Failure to do so could result in delisting.
- Regulatory Uncertainty: There is no assurance that APF530 will be approved upon resubmission, or that the company can raise the capital necessary to launch the product if approved.
Investor Verification Checklist
- Regulatory Timeline: Verify the date and outcome of the upcoming End of Review meeting with the FDA regarding the APF530 NDA resubmission.
- Capital Requirements: Assess the specific costs and timeline required to address the FDA's CRL deficiencies (sterilization changes, clinical studies) and determine if current cash reserves are sufficient.
- Financing Status: Monitor progress on securing additional funding (equity, debt, or collaboration) to extend the runway beyond the first quarter of 2011.
- Nasdaq Compliance: Track the stock price to determine if the company will meet the $1.00 minimum bid price requirement by November 15, 2010, to avoid delisting.
- Manufacturing Deficiencies: Confirm the status of corrective actions taken by third-party contract manufacturers regarding the FDA inspection deficiencies.